Skip to main content

Advertisement

SpringerLink
Log in

A meta-analysis on the levels of VILIP-1 in the CSF of Alzheimer’s disease compared to normal controls and other neurodegenerative conditions

  • Review
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Alzheimer’s disease (AD) is a progressing neurodegenerative disorder and the main cause of serious irreversible cognitive decline in elderly people. Visinin-like protein 1 (VILIP-1) is a member of the family of calcium-binding proteins and plays a crucial role in AD pathophysiology. Multiple studies have shown that CSF levels of VILIP-1 are increased in AD patients compared to normal controls, or other neurodegenerative conditions. We searched online databases for studies on the levels of VILIP-1 in the CSF of AD patients in comparison to normal controls, mild cognitive impairment (MCI) patients and Dementia with Lewy bodies (DLB) patients. A total of ten studies were used for the comparison between AD and controls, three studies for the comparison between AD and MCI, two studies for AD and DLB and two studies for the comparison between stable MCI and MCI progressed to AD. We found that VILIP-1 levels are significantly higher in AD compared to normal controls, but not to the other groups, and furthermore, they are significantly higher in patient with MCI progressed to AD, than in stable MCI patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Abbreviations

AD:

Alzheimer’s disease

MCI:

Mild cognitive impairment

AD-MCI:

Mild cognitive impairment progressed to Alzheimer’s disease

DLB:

Dementia with Lewy bodies

References

  1. Baloyannis SJ, Mavroudis I, Baloyannis IS et al (2016) Mammillary bodies in Alzheimer's disease: a golgi and electron microscope study. Am J Alzheimers Dis Other Dement 31:247–256

    Article  Google Scholar 

  2. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403

    Article  CAS  Google Scholar 

  3. Perl DP (2010) Neuropathology of Alzheimer’s disease. Mt Sinai J Med 77:32–42

    Article  Google Scholar 

  4. Mavroudis IA, Fotiou DF, Adipepe LF et al (2010) Morphological changes of the human purkinje cells and deposition of neuritic plaques and neurofibrillary tangles on the cerebellar cortex of Alzheimer's disease. Am J Alzheimers Dis Other Dement 25:585–591

    Article  Google Scholar 

  5. Jack CR Jr, Bennett DA, Blennow K et al (2016) A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87:539–547

    Article  CAS  Google Scholar 

  6. Gozes I (2017) Specific protein biomarker patterns for Alzheimer’s disease: improved diagnostics in progress. EPMA J 8:255–259

    Article  Google Scholar 

  7. Mroczko B, Groblewska M, Zboch M et al (2015) Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer’s disease. J Alzheimers Dis 43:1031–1037

    Article  CAS  Google Scholar 

  8. Sippy T, Cruz-Martin A, Jeromin A et al (2003) Acute changes in short-term plasticity at synapses with elevated levels of neuronal calcium sensor-1. Nat Neurosci 6:1031–1038

    Article  CAS  Google Scholar 

  9. Braunewell K, Riederer P, Spilker C et al (2001) Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord 12:110–116

    Article  CAS  Google Scholar 

  10. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 20:13

    Article  Google Scholar 

  11. Polanin JR, Hennessy EA, Tanner-Smith EE (2017) A review of meta-analysis packages in R. J Educ Behav Stat 42:206–242

    Article  Google Scholar 

  12. Zhang H, Ng KP, Therriault J et al (2018) Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease. Transl Neurodegener 7:23

    Article  Google Scholar 

  13. Babić Leko M, Borovečki F, Dejanović N et al (2016) Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment. J Alzheimers Dis 50:765–778

    Article  Google Scholar 

  14. Kester MI, Teunissen CE, Sutphen C et al (2015) Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimers Res Ther 7:59

    Article  Google Scholar 

  15. Luo X, Hou L, Shi H et al (2013) CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. J Neurochem 127:681–690

    Article  CAS  Google Scholar 

  16. Tarawneh R, Lee JM, Ladenson JH et al (2012) CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78:709–719

    Article  CAS  Google Scholar 

  17. Tarawneh R, D'Angelo G, Macy E et al (2011) Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 70:274–285

    Article  CAS  Google Scholar 

  18. Muszyński P, Kulczyńska-Przybik A, Borawska R et al (2017) The relationship between markers of inflammation and degeneration in the central nervous system and the blood–brain barrier impairment in Alzheimer's disease. J Alzheimers Dis 59:903–912

    Article  Google Scholar 

  19. Babić Leko M, Willumsen N, Nikolac Perković M et al (2018) Association of MAPT haplotype-tagging polymorphisms with cerebrospinal fluid biomarkers of Alzheimer's disease: a preliminary study in a croatian cohort. Brain Behav 8:e01128

    Article  Google Scholar 

  20. Mroczko B, Groblewska M, Zboch M et al (2015) Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease. J Alzheimers Dis 43:1031–1037

    Article  CAS  Google Scholar 

  21. O’Callaghan DW, Haynes LP, Burgoyne RD (2005) High affinity interaction of the N-terminal myristoylation motif of the neuronal calcium sensor protein hippocalcin with phosphatidyl inositol 4,5-bisphosphate. Biochem J 391:231–238

    Article  Google Scholar 

  22. Braunewell KH, Paul B, Altarche-Xifro W et al (2010) Interactions of visinin-like proteins with phosphoinositides. Aust J Chem 63:350–356

    Article  CAS  Google Scholar 

  23. Coussen F, Perrais D, Jaskolski F et al (2005) Coassembly of two GluR6 kainate receptor splice variants within a functional protein complex. Neuron 47:555–566

    Article  CAS  Google Scholar 

  24. Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74:363–396

    Article  CAS  Google Scholar 

  25. Schnurra I, Bernstein HG, Riederer P et al (2001) The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer’s disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer’s disease? Neurobiol Dis 8:900–909

    Article  CAS  Google Scholar 

  26. Chard PS, Bleakman D, Christakos S et al (1993) Calcium buffering properties of calbindin D28k and parvalbumin in rat sensory neurones. J Physiol 472:341–357

    Article  CAS  Google Scholar 

  27. Braunewell KH (2012) The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer’s disease-old wine in new bottle. Front Mol Neurosci 5:1–12

    Article  Google Scholar 

  28. Lee JM, Blennow K, Andreasen N et al (2008) The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 54:1617–1623

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leeds Teaching Hospitals NHS Trust, Leeds, UK

    Ioannis A. Mavroudis

  2. Medical School, University of Cyprus, Nicosia, Cyprus

    Ioannis A. Mavroudis

  3. Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Foivos Petridis, Symela Chatzikonstantinou, Eleni Karantali & Dimitris Kazis

Authors
  1. Ioannis A. Mavroudis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Foivos Petridis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Symela Chatzikonstantinou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eleni Karantali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dimitris Kazis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ioannis A. Mavroudis.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The present study is a meta-analysis of previous studies and therefore no ethical approval needed. All the studies included had taken ethical approval

Statement of human and animal right

The present study were carried out with full respect to human rights.

Informed consent

We confirm that the present study is based on the analysis of other studies which had obtained informed consent for all individuals.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mavroudis, I.A., Petridis, F., Chatzikonstantinou, S. et al. A meta-analysis on the levels of VILIP-1 in the CSF of Alzheimer’s disease compared to normal controls and other neurodegenerative conditions. Aging Clin Exp Res 33, 265–272 (2021). https://doi.org/10.1007/s40520-019-01458-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40520-019-01458-2

Keywords

Search

Navigation